Biocytogen Pharmaceuticals (SHA:688796, HKG:2315) posted 71.4 million yuan in net profit attributable to shareholders for the third quarter, up 8% from a year earlier.
EPS came in at 0.16 yuan, a Thursday filing with the Hong Kong Exchange showed.
For the three months ended Sept. 30, operating revenue was 461.4 million yuan, up 44% from the year-ago period, the drugmaker said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments